New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2014
07:19 EDTISIS, BIIBIsis to receive $9.3M in milestone payments for ongoing Phase 2 ISIS-SMN study
Isis Pharmaceuticals (ISIS) announced that the first child in the 12 mg group was dosed in the ongoing Phase 2 study evaluating ISIS-SMNRx in children with spinal muscular atrophy. Isis also announced that the first child was dosed in an open–label extension study, which is being offered to those children with SMA who have completed dosing in Isis' previous studies. Isis will receive two milestone payments totaling $7.3M for advancements in these studies. Isis also announced that dosing in the Phase 2 study in infants with SMA is being extended. Under the extension, infants who have completed the three initially scheduled study doses will be eligible to receive an additional dose of 12 mg. Isis announced that the first infant in the study has received a fourth dose of ISIS-SMNRx approximately six months after the three initial doses were completed. For this achievement, Isis will receive a $2M milestone payment from Biogen Idec (BIIB).
News For ISIS;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
07:32 EDTBIIBCubist names Perez CEO to succeed Bonney
Subscribe for More Information
October 15, 2014
09:57 EDTISISLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
October 14, 2014
11:23 EDTBIIBBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
October 13, 2014
07:12 EDTISISOligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
October 10, 2014
09:00 EDTISISOn The Fly: Pre-market Movers
Subscribe for More Information
05:22 EDTISISIsis Pharmaceuticals reports data from ISIS-SMN Rx Phase 2 study
Subscribe for More Information
October 9, 2014
07:02 EDTISISIsis Pharmaceuticals receives $18M milestone payment from GlaxoSmithKline
Subscribe for More Information
October 8, 2014
11:10 EDTISISOptions with increasing implied volatility
Subscribe for More Information
October 7, 2014
10:56 EDTISISOptions with increasing implied volatility
Subscribe for More Information
07:24 EDTBIIBAlliance for Regenerative Medicine
Subscribe for More Information
October 6, 2014
14:24 EDTISISIsis Pharmaceuticals volatility elevated into update on Phase 2 clinical studies
Isis Pharmaceuticals October weekly call option implied volatility is at 120, October is at 94, November is at 73, January is at 64; compared to its 26-week average of 65 according to Track Data, suggesting large price movement into management providing an update on the Phase 2 clinical studies of ISIS-SMN Rx results presented at the 19th International World Muscle Society Congress on October 10.
07:13 EDTISISMobile Marketing & Technology Magazine to hold a conference
Mobile Payments Conference is being held in Chicago on October 6-8.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use